Medexus Pharmaceuticals Inc. (TSX.V: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products, Medexus is building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin its growth for the next decade. The Company’s vision is to provide the best healthcare products to health care professionals and patients, through its core values of quality, innovation, customer service and teamwork. For more information, please visit the company’s website at www.medexus.com.
To view IBN’s virtual coverage of Medexus Pharmaceuticals and other presenters at the Sidoti Microcap Conference, as well as gain access to additional conference information and registration, visit https://ibn.fm/SidotiMay2021Portal.
Institutional, family office and high-net-worth investors, as well as RIAs, who wish to schedule a 1×1 meeting with the management of Medexus can contact the Sidoti conference team directly at [email protected].
About Medexus Pharmaceuticals Inc.
Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action.
For more information on Medexus, please contact:
Investor Relations (U.S.):
Crescendo Communications, LLC
Email: [email protected]
Investor Relations (Canada):
E-mail: [email protected]
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at the Sidoti Virtual Microcap Conference. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com